جستجوی استاد راهنمای دانشگاهی

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +۷ مورد دیگر

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

• Pharmacology
• Traditional Chinese Medicine
• Cancer Therapy
• +۷ مورد دیگر

Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.

• Nutritional Systems Biology
• Food Science
• Bioactive Compounds
• +۳ مورد دیگر

Prof. Veronika Somoza is a leading academic in Nutritional Systems Biology, currently affiliated with the University of Vienna and Technical University of Munich (TUM). She holds a professorship in Molecular Food Science and has led key research groups such as the Institute of Physiological Chemistry and the Christian Doppler Laboratory for Bioactive Aromatics. Her career includes roles at institutions like the German Research Institute for Food Chemistry (Garching) and the University of Wisconsin-Madison. Education: Diplom (Justus Liebig University Giessen, 1991), PhD (University of Vienna, 1995), Habilitation (Kiel University, 2002) Research Focus: Bioactive food compounds, flavor chemistry, taste receptor signaling, and gastrointestinal physiology Her work bridges food science and human health, particularly in understanding how food ingredients influence digestion, inflammation, and disease. Notable contributions include discoveries on bitter peptide effects on gastric acid secretion and flavor perception modulation. Awards: FEMA Excellence in Flavor Science (2016), ACS AGFD Fellow (2020), Hans Adolf Krebs Prize (2004) Prof. Somoza has pioneered methodologies in atomic force microscopy for foodborne virus detection and developed bitterness-masking compounds for pharmaceuticals. Her interdisciplinary approach integrates nanobiophysics with nutrition to advance functional food design and clinical applications.

Liang Zhaoمشاهده پروفایل

استاد

• Pharmacometrics
• Drug Delivery Modeling
• Artificial Intelligence in Drug Development
• +۵ مورد دیگر

Liang Zhao, PhD, MAS, MBA, is a Professor in the Department of Bioengineering and Therapeutic Sciences within the Schools of Pharmacy and Medicine at the University of California, San Francisco (UCSF). Prior to joining UCSF, he served as director of the Division of Quantitative Methods and Modeling (DQMM) in the Office of Research and Standards in the Office of Generic Drugs in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) from 2015 to 2024. His professional career spans over 19 years with experience at Pharsight, Bristol Myers Squibb (BMS), MedImmune, and the FDA. Dr. Zhao's research focuses on pharmacometrics, drug delivery modeling, and artificial intelligence-based tools that impact drug development and regulatory decision-making. His work encompasses mechanistic models for brain drug delivery, regulatory science modeling and simulation, AI-driven drug discovery and development, drug interactions, biological availability, generic drugs, clinical pharmacology, therapeutic equivalency, computer simulation, and FDA regulatory processes. He has pioneered innovative approaches including model master files for model sharing and model-integrated evidence for generic product development and approval. His research integrates machine learning tools into pharmacometrics to advance drug delivery and bioequivalence assessment methodologies. Dr. Zhao has published over 120 articles and book chapters in prestigious journals. His recent publications demonstrate strong focus on applying advanced modeling techniques, machine learning algorithms, and pharmacometric approaches to solve complex problems in drug development and regulatory science. His work shows consistent innovation in developing quantitative methods to enhance bioequivalence assessment, improve drug product characterization, and support regulatory decision-making for generic drugs. FDA Group Recognition Award, FDA, 2024 Gary Neil Prize for Innovation in Drug Development, American Society for Clinical Pharmacology & Therapeutics (ASCPT), 2023 Commissioner's Special Citation, FDA, 2021 Humanitarian Award, Victims' Rights Foundation, 2020 30+ FDA CDER team and Individual Awards, CDER, FDA, 2011 Academic Award for Executive MBA Class 2009, Judge Business School, University of Cambridge, 2011 Dr. Zhao leads the Zhao Lab at UCSF, which advances drug development and regulatory science through cutting-edge research in pharmacometrics, drug delivery modeling, and artificial intelligence. His work bridges academic research with regulatory applications, demonstrating leadership in translating scientific innovations into practical regulatory frameworks. His experience across industry, regulatory agencies, and academia provides a unique perspective on drug development challenges and opportunities.

Markus Brinkmannمشاهده پروفایل

دانشیار

• Exposure and risk assessment modelling
• Toxicokinetic modelling
• Aquatic ecotoxicology
• +۳ مورد دیگر

Dr. Markus Brinkmann is an Associate Professor in the School of Environment and Sustainability at the University of Saskatchewan, Canada, and Director of the Toxicology Centre. He holds the Centennial Enhancement Chair in Mechanistic Environmental Toxicology. His research focuses on exposure and risk assessment modeling, toxicokinetic modeling, and aquatic ecotoxicology, with an emphasis on understanding contaminant effects under realistic environmental conditions. Affiliations: Associate Professor, University of Saskatchewan Director, Toxicology Centre Member, Global Water Futures Program Member, Global Institute for Water Security Education: Ph.D. (Biology) - RWTH Aachen University, Germany (2015) M.Sc. (Ecotoxicology) - RWTH Aachen University, Germany (2011) B.Sc. (Biology) - RWTH Aachen University, Germany (2009) Research Interests: Dr. Brinkmann develops computational models to predict contaminant uptake, effects, and cross-species extrapolation. His work integrates toxicology, environmental chemistry, and hydrology to address challenges like flood-related contaminant remobilization and dioxin-like compound toxicity. Key areas include: Mechanistic toxicology of emerging contaminants (e.g., 6PPD-quinone, PFAS alternatives) Sediment toxicity and bioavailability Wastewater surveillance for public health monitoring Grant Highlights: Global Water Futures Program (2018-2023): Hydrological-exposure models for environmental risk assessment Genome Canada (2016-2020): EcoToxChip for chemical prioritization Banting Postdoctoral Fellowship (2016-2018) Awards: Friedrich-Wilhelm-Award (2016) SETAC GLB Young Scientists Award (2016 PhD, 2012 MSc) Borchers medal (2016) Leadership: He advises on strategic research partnerships between Canada and Germany and collaborates globally on projects like the EcoToxChip and Project House Water . His work bridges academic research with practical environmental management solutions.

Helma Wennemersمشاهده پروفایل

استاد

• Organic Chemistry
• Chemical Biology
• Peptide Chemistry
• +۵ مورد دیگر

Prof. Dr. Helma Wennemers serves as a Full Professor at ETH Zurich's Department of Chemistry and Applied Biosciences, leading the Laboratory for Organic Chemistry. Her research group operates from HCI H 313 at Vladimir Prelog Way 1-5/10 in Zurich, Switzerland, with active teaching responsibilities including Organic Chemistry I and Chemical Biology - Peptides for the Fall 2025 semester. Her research program centers on the intersection of organic chemistry and chemical biology , with particular emphasis on collagen triple helix engineering , peptide-catalyzed asymmetric synthesis , and development of chemical tools for tissue remodeling diagnostics . Key focus areas include designing hyperstable collagen heterotrimers for fibrosis monitoring, creating fluorophore-based probes for collagen cross-linking visualization, and pioneering organocatalytic methodologies for complex heterocycle synthesis. Her group actively explores how hydrophobic modifications and proline derivatives influence collagen stability and cellular uptake mechanisms. Analysis of her 15 most recent publications (2024-2025) reveals three dominant research trajectories: (1) collagen structural engineering for biomedical applications, (2) innovative peptide/organocatalysis enabling stereoselective transformations, and (3) chemical probe development targeting tissue remodeling processes. These works consistently integrate synthetic chemistry with biological validation, demonstrating translational potential in fibrosis diagnostics and regenerative medicine. While specific grant details aren't provided in available sources, her research program clearly supports advanced laboratory infrastructure including peptide synthesis facilities and photochemical reaction systems like the ETHos photoreactor. Her group maintains strong industry and clinical collaborations evident in applications targeting liver cancer cells and prostate cancer diagnostics. The Laboratory for Organic Chemistry functions as an interdisciplinary hub where synthetic organic chemists collaborate with biologists to develop collagen-based diagnostic platforms and catalytic systems. Current projects focus on lysyl oxidase-responsive probes for real-time tissue monitoring and engineered peptide catalysts for sustainable chemical synthesis under environmentally relevant conditions.

Parisa Hosseinzadehمشاهده پروفایل

استادیار

• Protein Design
• Computational Biochemistry
• Biosensors
• +۳ مورد دیگر

Parisa Hosseinzadeh is an Assistant Professor in the Department of Bioengineering at the University of Oregon. Her research focuses on computational protein design and structure-guided rational protein/peptide engineering, with applications in enzyme design, biosensors, and biomedical solutions. She holds a B.Sc. from the University of Tehran, a Ph.D. from the University of Illinois (advisor: Yi Lu), and a postdoc at the University of Washington in David Baker's lab. Her lab emphasizes interdisciplinary approaches at the intersection of computer science, chemistry, and biology, prioritizing diversity and inclusion in STEM. Key projects include designing cyclic peptides as enzyme inhibitors, developing methods for tuning redox potentials in metalloproteins, and creating tools to combat biomedical challenges. Lab members include postdocs, graduate students (e.g., Noora Azadvari, Andrew Powers), and undergraduates. Notable achievements include NSF grants, the Baxter Foundation Award, and the Hans Horse Meyer Award. The lab also emphasizes mentorship, collaborative culture, and outreach initiatives.

Xiaodong Wangمشاهده پروفایل

استاد

• Medicinal Chemistry
• Drug Discovery
• Kinase Inhibitors
• +۳ مورد دیگر

Xiaodong Wang is a Professor at the Center for Integrative Chemical Biology and Drug Discovery within the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. His research program focuses on developing innovative drug leads and candidates targeting novel protein kinases and other molecular targets identified by UNC faculty and external investigators. Dr. Wang's research interests center on structure- and ligand-based drug design approaches for developing therapeutic compounds, particularly kinase inhibitors targeting the TAM family (TYRO3, AXL, MERTK). His laboratory has successfully applied these methodologies to deliver compounds to clinical trials, including MerTK inhibitors and IDH1 inhibitors developed in collaboration with NCATS. Current research continues to focus on structure-based drug design for novel targets, with particular emphasis on cancer therapeutics and molecular imaging agents. Analysis of Dr. Wang's recent publications (2023-2025) reveals a strong focus on developing selective kinase inhibitors, particularly targeting the TAM receptor family (TYRO3, AXL, MERTK) for various cancer types including leukemia, Ewing sarcoma, and melanoma. His work spans multiple disciplines including medicinal chemistry, cancer biology, immunology, and molecular imaging, with recent publications appearing in high-impact journals such as Journal of Medicinal Chemistry, Nature Communications, and Leukemia. Dr. Wang maintains active collaborations across UNC-Chapel Hill and with external institutions, working with researchers in pharmacology, oncology, immunology, and structural biology. His laboratory develops both small molecule inhibitors and imaging agents, with several compounds progressing toward clinical applications. Contact information: xiaodonw@email.unc.edu | Wang Lab website

• Urban Horticulture
• Ecosystem Services
• Urban Forestry
• +۶ مورد دیگر

Professor Jill Edmondson serves as a Professor of Ecosystem Sustainability and NERC Knowledge Exchange Fellow at the School of Biosciences, University of Sheffield, where she has been a Senior Lecturer since 2021. Her research focuses on enhancing ecosystem sustainability and resilience in urban and agricultural contexts through interdisciplinary approaches bridging soil science, plant ecology, and social dimensions. Her core research pillars include: Urban Horticulture , where she leads the national MYHarvest citizen science project quantifying home-grown food production while assessing ecosystem co-benefits and soil pollutant risks; Soil Carbon Dynamics , specializing in black carbon's role in urban soil carbon sequestration; and Urban Forest Ecology , investigating how pollution and infrastructure encasement impact tree health and ecosystem services like heat mitigation. Her work consistently integrates field studies with policy-relevant applications for city planning. Analysis of her 2020-2025 publications reveals intensifying focus on climate adaptation, with dominant themes including urban food security quantification, soil contaminant bioavailability, green infrastructure performance, and urban tree resilience. Methodologically, she pioneers citizen science integration and interdisciplinary field measurements, yielding actionable insights for urban sustainability policy. Her major recognitions include: NERC Knowledge Exchange Fellow (2022-present) EPSRC Living with Environmental Change Fellow (2016-2021) Professor Edmondson supervises undergraduate literature reviews and research projects across multiple programs (MBiolSci, MEnvSci, MSc, MRes), mentoring the next generation of sustainability scientists. Her grant portfolio features competitive fellowships supporting urban ecosystem research with direct policy applications through partnerships with local governments and environmental NGOs. She directs the MYHarvest citizen science initiative and collaborates extensively with the University of Sheffield's Institute for Sustainable Food, leading a multidisciplinary team spanning soil science, ecology, and engineering to develop evidence-based strategies for resilient urban ecosystems.

Kathryn A. Whiteheadمشاهده پروفایل

استاد

• Drug Delivery
• RNA Therapeutics
• Bionanotechnology
• +۴ مورد دیگر

Dr. Kathryn A. Whitehead is a Professor in the Department of Chemical Engineering and holds a courtesy appointment in the Department of Biomedical Engineering at Carnegie Mellon University. She joined the faculty in 2012 after completing postdoctoral training at MIT. Her research focuses on engineering drug delivery systems for RNA therapeutics, maternal-infant health, and overcoming biological barriers to enhance drug efficacy. Key areas include lipid nanoparticle (LNP) design for mRNA delivery, intestinal permeation enhancement, and leveraging maternal milk cells for therapeutic applications. Education: H.B.Ch.E., University of Delaware (2002); Ph.D., University of California, Santa Barbara (2007); Postdoctoral Fellow, MIT (2008–2012). Research Interests: Drug delivery systems, RNA interference, bionanotechnology, personalized medicine, and translational nanomedicine for diseases such as cancer and diabetes. Her lab develops novel LNPs for targeted delivery to tissues like the liver, brain, and pancreas. Awards and Recognition: AIMBE Fellow, DARPA Young Faculty Award (2016), CMBE Young Innovator Award (2016), MIT Technology Review Innovator Under 35 (2014), and NIH Director’s New Innovator Award. Her work has been cited over 9,000 times, with patents in RNA delivery and permeation enhancers. Lab Members: Active researchers include Ph.D. students, postdocs, and undergraduates working on projects such as LNP formulation, maternal milk cell biology, and siRNA therapies. Notable alumni have advanced to roles at Moderna Therapeutics, Verve Therapeutics, and academic institutions. Grants and Funding: Supported by NIH, DARPA, and industry partnerships. Current projects include NIH grants on pregnancy-safe mRNA delivery and DARPA funding for maternal-infant therapeutics.

Ken Oakesمشاهده پروفایل

دانشیار

• Environmental Remediation
• Aquatic Toxicology
• Nanotechnology
• +۴ مورد دیگر

Ken Oakes is an Associate Professor in the Biology Department at Cape Breton University (CBU) and holds the Industrial Research Chair in Environmental Remediation. He specializes in environmental toxicology, nanotechnology, and aquatic ecosystems. With a Ph.D. from the University of Guelph and postdoctoral training at the University of Waterloo, his research focuses on reactive oxygen species, water treatment, and pollution mitigation. He has over 60 peer-reviewed publications and supervised numerous graduate/undergraduate theses. Key research areas include photocatalytic water treatment using TiO₂ composites, surface-enhanced Raman spectroscopy (SERS) for contaminant detection, and transdermal drug delivery via polymeric microneedles. His work addresses industrial effluent impacts on marine ecosystems and sustainable antifouling technologies. Recent studies investigate nanomaterials for environmental remediation and biomedical applications. Dr. Oakes has contributed to projects assessing pulp mill effluent effects on coastal ecosystems, copper-based Fenton chemistry for biofilm removal, and uranium extraction from water. His lab develops innovative solutions for environmental challenges, combining engineering, chemistry, and biology disciplines. Funding sources include industrial partnerships and academic grants focused on clean technologies.

Martin Frommمشاهده پروفایل

استاد

• Biomarkers for transporter-mediated drug-drug interactions
• Medication safety (oncology, geriatrics)
• Mass spectrometry and metabolomics
• +۲ مورد دیگر

Martin Fromm is a Professor of Clinical Pharmacology and Toxicology at Friedrich-Alexander University Erlangen-Nürnberg, where he has served as Director of the Institute of Experimental and Clinical Pharmacology and Toxicology since 2004. His career includes prior roles as Acting Professor (2002–2004), Group Leader (1999–2002), and postdoctoral fellowships at the Dr. Margarete-Fischer-Bosch Institute (1992–1996) and Vanderbilt University (1997–1999). Research Focus: Mechanisms of variable drug effects, drug transporters, medication safety, and biomarker development for transporter-mediated drug interactions. Publications: Over 170 original articles and 49 reviews with an h-index of 76 (24,000+ citations). Leadership: Chair of the University Hospital Erlangen's drug utilization committee and steering board of the Center of Clinical Studies. Scientific Awards: Top 3% Highly Cited Researcher (AD Scientific Index 2022–2024) Top 2% Highly Cited Researcher (Stanford List 2023) MSD Health Award (2021) Paul-Martini-Award (2001) Presidential Trainee Award (1998) Research Trends: His recent work integrates metabolomics, machine learning (LC-MS methods), and clinical studies to enhance medication safety in oncology and geriatrics. Earlier studies focus on transporter proteins (e.g., OCT2, MATE1, P-glycoprotein) and their role in drug absorption, metabolism, and interactions. Grants & Collaborations: Funded by DFG, BMBF, BMG, and Deutsche Krebshilfe. Active in ethics committees and clinical pharmacology societies.

• Biotechnology
• Biocatalysis
• Enzyme Engineering
• +۴ مورد دیگر

Pedro Carlos De Barros Fernandes is an Associate Professor at Universidade Lusófona , Deputy Director of the 1st cycle in Biotechnology, and an integrated researcher at the Institute of Bioengineering and Biosciences (iBB-IST). He holds a PhD in Biotechnology (1999) and a Master in Biotechnology/Biochemical Engineering (1994) from Universidade Técnica de Lisboa (IST), along with a Chemical Engineering degree from IST (1989). A member of the Order of Engineers (ID 24667), he co-founded Biotrend, a Portuguese bioprocess development company. Education PhD in Biotechnology (1999), Universidade Técnica de Lisboa MSc in Biotechnology (1994), Instituto Superior Técnico BSc in Chemical Engineering (1989), Instituto Superior Técnico Research Interests span biocatalysis, enzyme immobilization for food and pharmaceutical applications, marine biotechnology, microfluidic device development for biosensing, and steroid bioconversions using mycobacterial systems. His work integrates process engineering principles with sustainable bioprocessing techniques. Publication Trends show a focus on microreactor technology, enzyme stabilization in non-conventional media, marine-derived biocatalysts, and food waste valorization. Key themes include biocatalytic process intensification, aqueous two-phase systems for biomolecule purification, and sustainable carbon sources for biopolymer production. Scientific Awards UTL/Santander Totta Scientific Award in Biological Engineering (2011) Advising has included supervision of 5 doctoral theses and over 32 master’s theses. His expertise extends to peer-reviewing scientific articles and evaluating R&D projects. Labs & Teams are associated with iBB-IST (Institute of Bioengineering and Biosciences) and BioRG (Universidade Lusófona), with contributions to the Ciência Viva program for science dissemination.

Timothy B. Curryمشاهده پروفایل

استاد

• Autonomic Nervous System
• Cardiovascular Physiology
• Insulin Sensitivity
• +۴ مورد دیگر

Timothy B. Curry, M.D., Ph.D., is a Professor of Anesthesiology and Assistant Professor of Physiology at Mayo Clinic, Rochester, Minnesota. He holds academic roles including Vice Chair for Clinical Practice in the Department of Anesthesiology and Perioperative Medicine, and leads initiatives in individualized medicine through the Center for Individualized Medicine. His research focuses on autonomic nervous system regulation of cardiovascular and metabolic functions, employing advanced techniques such as microneurography and glucose clamping. Key interests include perioperative outcomes, environmental physiology, and hyperbaric medicine. Education: B.A. in Molecular Biology & Biochemistry (Middlebury College) M.D./Ph.D. via Medical Scientist Training Program (SUNY Buffalo) Residency in Anesthesiology (Mayo Clinic) Research Interests: Dr. Curry’s work spans autonomic nervous system physiology, metabolic syndrome mechanisms, and perioperative glycemic control. He leads the Human Integrative Physiology and Clinical Pharmacology Laboratory and collaborates globally on microneurography studies. Recent projects include investigating cerebral oxygen metabolism under hypoxia and developing genomic medicine training programs (COGENT). Awards: Emerald Award for Excellence (2015) Mayo Excellence in Leadership Award (2009) Multiple research and teaching accolades Grants & Leadership: Co-director of Mayo’s Clinomics Program, Team Leader for Perioperative Glucose Management, and Chair of multiple committees overseeing clinical practice and research. Labs & Teams: Directs the Human Integrative Physiology Lab and collaborates with the Clinical Research Unit. Active in multidisciplinary teams addressing autonomic dysfunction and precision medicine.

Joonhyuk Suhمشاهده پروفایل

استادیار

• Food Science
• Analytical Chemistry
• Metabolomics
• +۵ مورد دیگر

Joonhyuk Suh is an Assistant Professor in the Department of Food Science & Technology at the University of Georgia's College of Agricultural & Environmental Sciences. His research focuses on applying analytical chemistry and metabolomics/flavoromics to enhance food flavor, quality, and safety. Research Interests : Multidisciplinary food chemistry analysis Metabolite and flavor profiling Nut and fruit quality evaluation Dairy product flavor chemistry Food safety biomarkers Recent Publication Trends (2025-2022) show expertise in: Metabolomic evaluation of agricultural products Flavor chemistry in tropical fruits and nuts Food processing safety and contaminant analysis Plant-based food characterization Microbiome and nutritional interventions